ReviewBiochemistry and biophysics reports2025
Current literature support and opposition for therapeutic use of selenium supplementation in autoimmune thyroid conditions.
Review in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Selenium: Could It Be the Game-Changer for Ocular Surface and Anterior Chamber in Graves' Disease?Beyoglu eye journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review investigates the correlation between selenium status and thyroid conditions, specifically focusing on autoimmune thyroid diseases (AITD) including Hashimoto's Thyroiditis (HT) and Graves' Disease (GD). After a meticulous analysis of 14 research studies, we explored the impact of selenium levels and supplementation on several thyroid-specific parameters and overall disease progression. Several studies indicated a notable inverse correlation between selenium deficiency and the prevalence and severity of AITD. In particular, HT patients showed consistent improvement with selenium supplementation, suggesting its potential as a therapeutic agent. However, the effect of selenium on GD was not as clear, with some studies indicating no significant correlation. These inconsistent effects demonstrate how nuanced AITD treatment must be. It also shows that selenium plays a varied role in thyroid health. The findings in this review serve as an example of how micronutrient intake is important in thyroid disease management. The nuances of these treatments support a need for more patient-centered and individualized treatment plans, which may be further helped by detailed research into proper dosing and administration strategies. Specific patient populations may benefit from selenium supplementation, though the variability in outcomes points to a need for vigilance in the clinical setting. Importantly, the ability to personalize supplementation depends on establishing a reliable method for detecting selenium deficiency or status. Future clinical guidelines should emphasize the necessity of a solid diagnostic framework that allows for precise monitoring, ensuring that selenium supplementation is appropriately justified and tailored to individual patient needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.